Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Common Equity (2017 - 2025)

Historic Common Equity for Q32 Bio (QTTB) over the last 9 years, with Q3 2025 value amounting to -$18.4 million.

  • Q32 Bio's Common Equity fell 20083.63% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year decrease of 20083.63%. This contributed to the annual value of $5.7 million for FY2024, which is 10310.24% up from last year.
  • Latest data reveals that Q32 Bio reported Common Equity of -$18.4 million as of Q3 2025, which was down 20083.63% from -$12.2 million recorded in Q2 2025.
  • Q32 Bio's 5-year Common Equity high stood at $266.3 million for Q1 2022, and its period low was -$182.9 million during Q4 2023.
  • Over the past 5 years, Q32 Bio's median Common Equity value was $33.5 million (recorded in 2024), while the average stood at $60.0 million.
  • Per our database at Business Quant, Q32 Bio's Common Equity tumbled by 20277.73% in 2023 and then soared by 13553.58% in 2024.
  • Quarter analysis of 5 years shows Q32 Bio's Common Equity stood at $169.7 million in 2021, then rose by 4.91% to $178.0 million in 2022, then tumbled by 202.78% to -$182.9 million in 2023, then soared by 103.1% to $5.7 million in 2024, then crashed by 425.07% to -$18.4 million in 2025.
  • Its Common Equity stands at -$18.4 million for Q3 2025, versus -$12.2 million for Q2 2025 and -$4.0 million for Q1 2025.